Whether these immune cells could be triggered against the DT cells is still under investigation; in particular the activity of the combination of nivolumab (an antibody targeting programmed cell death protein 1, PD-1) and ipilimumab (an antibody targeting cytotoxic T-lymphocyte-associated protein 4, CTLA-4) is being investigated in a large multicohort trial recruiting patients affected by rare cancers, including DT [NCT02834013]. This evidence concerns the gene PDCD1 and cancer.